Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic pipeline in nonalcoholic steatohepatitis
Raj Vuppalanchi, Mazen Noureddin, Naim Alkhouri, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 6, pp. 373-392
Closed Access | Times Cited: 231

Showing 1-25 of 231 citing articles:

Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association
P. Barton Duell, Francine K. Welty, Michael Miller, et al.
Arteriosclerosis Thrombosis and Vascular Biology (2022) Vol. 42, Iss. 6
Open Access | Times Cited: 371
Immune cell-mediated features of non-alcoholic steatohepatitis
Thierry Huby, Emmanuel L. Gautier
Nature reviews. Immunology (2021) Vol. 22, Iss. 7, pp. 429-443
Open Access | Times Cited: 370
Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease – novel insights into cellular communication circuits
Moritz Peiseler, Robert F. Schwabe, Jochen Hampe, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 4, pp. 1136-1160
Open Access | Times Cited: 287
Challenges and opportunities in NASH drug development
Stephen A. Harrison, Alina M. Allen, Julie Dubourg, et al.
Nature Medicine (2023) Vol. 29, Iss. 3, pp. 562-573
Closed Access | Times Cited: 192
AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review
Michelle T. Long, Mazen Noureddin, Joseph K. Lim
Gastroenterology (2022) Vol. 163, Iss. 3, pp. 764-774.e1
Open Access | Times Cited: 178
Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment
Josep M. Llovet, Catherine E. Willoughby, Amit G. Singal, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 8, pp. 487-503
Closed Access | Times Cited: 177
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial
Naim Alkhouri, Robert Herring, Heidi Kabler, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 3, pp. 607-618
Open Access | Times Cited: 140
Soluble TREM2 levels reflect the recruitment and expansion of TREM2+ macrophages that localize to fibrotic areas and limit NASH
Tim Hendrikx, Florentina Porsch, Máté G. Kiss, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 5, pp. 1373-1385
Closed Access | Times Cited: 111
Breakthroughs in therapies for NASH and remaining challenges
Vlad Ratziu, Sven Francque, Arun J. Sanyal
Journal of Hepatology (2022) Vol. 76, Iss. 6, pp. 1263-1278
Open Access | Times Cited: 104
Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis
Delilah Hendriks, Jos F. Brouwers, Karien M. Hamer, et al.
Nature Biotechnology (2023) Vol. 41, Iss. 11, pp. 1567-1581
Open Access | Times Cited: 99
Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease
Gong Feng, Luca Valenti, Vincent Wai‐Sun Wong, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 21, Iss. 1, pp. 46-56
Closed Access | Times Cited: 91
Understanding the cellular interactome of non-alcoholic fatty liver disease
Sebastian Wallace, Frank Tacke, Robert F. Schwabe, et al.
JHEP Reports (2022) Vol. 4, Iss. 8, pp. 100524-100524
Open Access | Times Cited: 79
Healthcare and socioeconomic costs of NAFLD: A global framework to navigate the uncertainties
Alina M. Allen, Jeffrey V. Lazarus, Zobair M. Younossi
Journal of Hepatology (2023) Vol. 79, Iss. 1, pp. 209-217
Open Access | Times Cited: 76
Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease
Julian M. Yabut, Daniel J. Drucker
Endocrine Reviews (2022) Vol. 44, Iss. 1, pp. 14-32
Open Access | Times Cited: 69
Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression
Adrien Guillot, Marc Winkler, Milessa Silva Afonso, et al.
Hepatology (2023) Vol. 78, Iss. 1, pp. 150-166
Closed Access | Times Cited: 54
The intestine as an endocrine organ and the role of gut hormones in metabolic regulation
Rula Bany Bakar, Frank Reimann, Fiona M. Gribble
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 12, pp. 784-796
Closed Access | Times Cited: 53
Signaling pathways in macrophages: molecular mechanisms and therapeutic targets
Ming Li, Mengjie Wang, Yuanjia Wen, et al.
MedComm (2023) Vol. 4, Iss. 5
Open Access | Times Cited: 42
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies
Michail Kokkorakis, Emir Muzurović, Špela Volčanšek, et al.
Pharmacological Reviews (2024) Vol. 76, Iss. 3, pp. 454-499
Open Access | Times Cited: 30
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Maximilian Huttasch, Michael Roden, S. Kahl
Metabolism (2024) Vol. 157, pp. 155937-155937
Open Access | Times Cited: 29
MASH clinical trials and drugs pipeline: An impending tsunami
Mazen Noureddin
Hepatology (2024)
Closed Access | Times Cited: 17
Metabolic Dysfunction–Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options
Piero Portincasa, Mohamad Khalil, Laura Mahdi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 5640-5640
Open Access | Times Cited: 16
SLC7A11-ROS/αKG-AMPK axis regulates liver inflammation through mitophagy and impairs liver fibrosis and NASH progression
Tingting Lv, Xiude Fan, Chang He, et al.
Redox Biology (2024) Vol. 72, pp. 103159-103159
Open Access | Times Cited: 15
Vicious Cycle‐Breaking Lipid Nanoparticles Remodeling Multicellular Crosstalk to Reverse Liver Fibrosis
Lingfeng Zhang, Wen‐Qi Deng, Qing‐Wen Huang, et al.
Advanced Materials (2024) Vol. 36, Iss. 16
Closed Access | Times Cited: 14
Integrative clinical and preclinical studies identify FerroTerminator1 as a potent therapeutic drug for MASH
Liang Tao, Xinquan Yang, Chaodong Ge, et al.
Cell Metabolism (2024) Vol. 36, Iss. 10, pp. 2190-2206.e5
Open Access | Times Cited: 14
Estimated Burden of Metabolic Dysfunction–Associated Steatotic Liver Disease in US Adults, 2020 to 2050
Phuc Le, Moosa Tatar, Srinivasan Dasarathy, et al.
JAMA Network Open (2025) Vol. 8, Iss. 1, pp. e2454707-e2454707
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top